Display options
Share it on

JCI Insight. 2017 Apr 20;2(8). doi: 10.1172/jci.insight.89635. eCollection 2017 Apr 20.

MPEG1/perforin-2 mutations in human pulmonary nontuberculous mycobacterial infections.

JCI insight

Ryan M McCormack, Eva P Szymanski, Amy P Hsu, Elena Perez, Kenneth N Olivier, Eva Fisher, E Brook Goodhew, Eckhard R Podack, Steven M Holland

Affiliations

  1. Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, Florida, USA.
  2. Laboratory of Clinical Infectious Diseases, NIAID, NIH.
  3. Cardiovascular and Pulmonary Branch, NHLBI, NIH, Bethesda, Maryland, USA.

PMID: 28422754 PMCID: PMC5396519 DOI: 10.1172/jci.insight.89635

Abstract

Perforin-2 is a highly conserved pore-forming protein encoded by macrophage expressed gene 1 (MPEG1). A number of studies have shown that Perforin-2-deficient mice are unable to survive following a bacterial challenge that is nonlethal in WT mice. There is also recent evidence that Mpeg1+/- heterozygous mice display an intermediate killing ability compared with Mpeg1 WT and Mpeg1-/- mice. Despite these in vivo findings, to date, no perforin-2 deficiencies have been associated with human disease. Here, we report four patients with persistent nontuberculous mycobacterial infection who had heterozygous MPEG1 mutations. In vitro, neutrophils, macrophages, and B cells from these patients were unable to kill Mycobacterium avium as efficiently as normal controls. CRISPR mutagenesis validated the deleterious antibacterial activity of these mutations. These data suggest that perforin-2 haploinsufficiency may contribute to human susceptibility to infections with intracellular bacteria.

Keywords: Genetics; Infectious disease

References

  1. Fish Shellfish Immunol. 2014 Aug;39(2):263-72 - PubMed
  2. Immunol Res. 2013 Dec;57(1-3):268-78 - PubMed
  3. Elife. 2015 Sep 29;4:null - PubMed
  4. Chest. 1992 Jun;101(6):1605-9 - PubMed
  5. J Allergy Clin Immunol. 2008 Dec;122(6):1043-51; quiz 1052-3 - PubMed
  6. Am J Respir Crit Care Med. 2012 Apr 15;185(8):881-6 - PubMed
  7. Am J Respir Crit Care Med. 2008 Nov 15;178(10):1066-74 - PubMed
  8. Methods Mol Biol. 2012;844:183-7 - PubMed
  9. Elife. 2015 Sep 24;4:null - PubMed
  10. Genome Res. 2005 Jul;15(7):901-13 - PubMed
  11. J Exp Med. 1952 Aug;96(2):137-50 - PubMed
  12. Semin Respir Crit Care Med. 2013 Feb;34(1):110-23 - PubMed
  13. Mol Immunol. 2011 Aug;48(14):1643-55 - PubMed
  14. J Interferon Cytokine Res. 2014 May;34(5):307-17 - PubMed
  15. Am J Respir Crit Care Med. 2015 Sep 1;192(5):618-28 - PubMed
  16. Am J Respir Crit Care Med. 2003 Mar 15;167(6):828-34 - PubMed
  17. Am J Respir Crit Care Med. 2004 Feb 15;169(4):459-67 - PubMed
  18. Nat Methods. 2010 Apr;7(4):248-9 - PubMed
  19. J Innate Immun. 2013;5(2):185-94 - PubMed
  20. Infect Immun. 2013 Aug;81(8):3045-54 - PubMed
  21. Crit Rev Microbiol. 1990;17(4):305-27 - PubMed
  22. Nature. 2016 Aug 17;536(7616):285-91 - PubMed
  23. Am J Respir Crit Care Med. 2003 Mar 15;167(6):835-40 - PubMed
  24. Infect Immun. 2016 Mar 24;84(4):1083-91 - PubMed
  25. J Clin Immunol. 2015 Jul;35(5):445-8 - PubMed
  26. Blood. 1995 Mar 15;85(6):1620-9 - PubMed
  27. Nat Genet. 2014 Mar;46(3):310-5 - PubMed
  28. PLoS One. 2013 Jun 04;8(6):e65102 - PubMed
  29. Nat Protoc. 2009;4(7):1073-81 - PubMed
  30. Emerg Infect Dis. 2009 Oct;15(10):1556-61 - PubMed
  31. Blood. 2016 Apr 28;127(17):2113-21 - PubMed
  32. Curr Top Microbiol Immunol. 2013;374:211-41 - PubMed
  33. Nat Protoc. 2013 Nov;8(11):2281-308 - PubMed
  34. J Innate Immun. 2015;7(2):136-52 - PubMed
  35. Br Med Bull. 1988 Jul;44(3):801-13 - PubMed

Publication Types

Grant support